(Q33878662)

29 July 2017

1 reference

title

Turning a corner on HIV neutralization? (English)

1 reference

29 July 2017

J H Nunberg

1

1 reference

29 July 2017

K E Follis

series ordinal

2

1 reference

29 July 2017

M Trahey

series ordinal

3

1 reference

29 July 2017

R A LaCasse

series ordinal

4

1 reference

29 July 2017

1 February 2000

1 reference

29 July 2017

Microbes and Infection

1 reference

29 July 2017

2

1 reference

29 July 2017

2

1 reference

29 July 2017

213-221

1 reference

Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Continued utilization of CCR5 coreceptor by a newly derived T-cell line-adapted isolate of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Jitters jeopardize AIDS vaccine trials

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Evaluation of Monoclonal Antibodies to Human Immunodeficiency Virus Type 1 Primary Isolates by Neutralization Assays: Performance Criteria for Selecting Candidate Antibodies for Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

HIV-1 neutralizing antibodies: how full is the bottle?

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Fusion-competent vaccines: broad neutralization of primary isolates of HIV

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

HIV and SIV gp120 binding does not predict coreceptor function

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Capture of an early fusion-active conformation of HIV-1 gp41

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Lipid membrane fusion induced by the human immunodeficiency virus type 1 gp41 N-terminal extremity is determined by its orientation in the lipid bilayer

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Mutational analysis of the fusion peptide of the human immunodeficiency virus type 1: identification of critical glycine residues.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

HIV entry and its inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Core structure of gp41 from the HIV envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Atomic structure of the ectodomain from HIV-1 gp41

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

The central structural feature of the membrane fusion protein subunit from the Ebola virus glycoprotein is a long triple-stranded coiled coil

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

HIV Type 1 Variation in World Health Organization-Sponsored Vaccine Evaluation Sites: Genetic Screening, Sequence Analysis, and Preliminary Biological Characterization of Selected Viral Strains

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Identification of a major co-receptor for primary isolates of HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2800%2900267-7

7 January 2021

10.1016/S1286-4579(00)00267-7

Identifiers

DOI

1 reference

29 July 2017

1 reference